Page 42 - AN-4-2

Advanced Neurology SARS-CoV-2 mechanisms of neurological impact

154. Andreu M, Matti N, Bramlett HM, Shi Y, Gajavelli S, impact on Alzheimer’s disease pathology. J Neurochem.
Dietrich WD. Dose‑dependent modulation of microglia 2024;168(10):3415‑3429.
activation in rats after penetrating traumatic brain injury doi: 10.1111/jnc.15985
(pTBI) by transplanted human neural stem cells. PLoS One.
2023;18(5):e0285633. 165. A SS, Thapliyal A, Pant K. In-silico modeling of the interplay
between APOE4, NLRP3, and ACE2-SPIKE complex
doi: 10.1371/journal.pone.0285633
in neurodegeneration between Alzheimer and SARS-
155. Fernandez-Castaneda A, Lu P, Geraghty AC, et al. Mild CoV: Implications for understanding pathogenesis and
respiratory COVID can cause multi-lineage neural cell and developing therapeutic strategies. J Biomol Struct Dyn.
myelin dysregulation. Cell. 2022;185(14):2452‑2468.e16. 2024;42(18):9678‑9690.
doi: 10.1016/j.cell.2022.06.008 doi: 10.1080/07391102.2023.2252094
156. Fontes-Dantas FL, Fernandes GG, Gutman EG, et al. 166. Chen F, Ke Q, Wei W, Cui L, Wang Y. Apolipoprotein E and
SARS-CoV-2 spike protein induces TLR4-mediated long- viral infection: Risks and mechanisms. Mol Ther Nucleic
term cognitive dysfunction recapitulating post-COVID-19 Acids. 2023;33:529‑542.
syndrome in mice. Cell Rep. 2023;42(3):112189.
doi: 10.1016/j.omtn.2023.07.031
doi: 10.1016/j.celrep.2023.112189
167. Xia X, Wang Y, Zheng J. COVID‑19 and Alzheimer’s disease:
157. Xu G, Li Y, Zhang S, et al. SARS-CoV-2 promotes How one crisis worsens the other. Transl Neurodegener.
RIPK1 activation to facilitate viral propagation. Cell Res. 2021;10(1):15.
2021;31(12):1230‑1243.
doi: 10.1186/s40035-021-00237-2
doi: 10.1038/s41422-021-00578-7
168. Blackmon K, Day GS, Powers HR, et al. Neurocognitive
158. Qin J, Ma Z, Chen X, Shu S. Microglia activation in central screening in patients following SARS-CoV-2 infection:
nervous system disorders: A review of recent mechanistic Tools for triage. Res Sq. [Preprint]. 2022.
investigations and development efforts. Front Neurol. doi: 10.21203/rs.3.rs-1127420/v1
2023;14:1103416.
169. Ciaccio M, Lo Sasso B, Scazzone C, et al. COVID-19 and
doi: 10.3389/fneur.2023.1103416
Alzheimer’s disease. Brain Sci. 2021;11(3):305.
159. Almutairi MM, Sivandzade F, Albekairi TH, Alqahtani F,
Cucullo L. Neuroinflammation and its impact on the doi: 10.3390/brainsci11030305
pathogenesis of COVID-19. Front Med (Lausanne). 170. Reiken S, Sittenfeld L, Dridi H, Liu Y, Liu X, Marks AR.
2021;8:745789. Alzheimer’s-like signaling in brains of COVID-19 patients.
Alzheimers Dement. 2022;18(5):955‑965.
doi: 10.3389/fmed.2021.745789
doi: 10.1002/alz.12558
160. Emrani S, Arain HA, DeMarshall C, Nuriel T. APOE4 is
associated with cognitive and pathological heterogeneity 171. Pszczolowska M, Walczak K, Miskow W, et al. Molecular
in patients with Alzheimer’s disease: A systematic review. cross-talk between long COVID-19 and Alzheimer’s disease.
Alzheimers Res Ther. 2020;12(1):141. Geroscience. 2024;46(3):2885‑2899.
doi: 10.1186/s13195-020-00712-4 doi: 10.1007/s11357-024-01096-1
161. Liu N, Sun J, Wang X, Zhao M, Huang Q, Li H. The 172. Narayanan SN, Padiyath S, Chandrababu K, et al. Neurological,
impact of dementia on the clinical outcome of COVID-19: psychological, psychosocial complications of long-COVID
A systematic review and meta-analysis. J Alzheimers Dis. and their management. Neurol Sci. 2024; 46:1‑23.
2020;78(4):1775‑1782. doi: 10.1007/s10072-024-07854-5
doi: 10.3233/JAD-201016 173. Crivelli L, Palmer K, Calandri I, et al. Changes in cognitive
162. Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 genotype functioning after COVID-19: A systematic review and
predicts severe COVID-19 in the UK biobank community meta-analysis. Alzheimers Dement. 2022;18(5):1047‑1066.
cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2231‑2232.
doi: 10.1002/alz.12644
doi: 10.1093/gerona/glaa131
174. Scialo F, Daniele A, Amato F, et al. ACE2: The major cell
163. Chen F, Chen Y, Ke Q, et al. ApoE4 associated with severe entry receptor for SARS-CoV-2. Lung. 2020;198(6):867‑877.
COVID-19 outcomes via downregulation of ACE2 and doi: 10.1007/s00408-020-00408-4
imbalanced RAS pathway. J Transl Med. 2023;21(1):103.
175. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis G, van
doi: 10.1186/s12967-023-03945-7
Goor H. Tissue distribution of ACE2 protein, the functional
164. Furman S, Green K, Lane TE. COVID-19 and the receptor for SARS coronavirus. A first step in understanding

Volume 4 Issue 2 (2025) 36 doi: 10.36922/an.4909